We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
-2.03%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.48B
AUM Growth
-$380M
(-13%)
Cap. Flow
-$210M
Cap. Flow
% of AUM
-8.45%
Top 10 Holdings %
Top 10 Hldgs %
29.58%
Holding
106
New
13
Increased
24
Reduced
44
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$67.1M |
| 2 |
Cigna
CI
|
+$59.2M |
| 3 |
UnitedHealth
UNH
|
+$55.2M |
| 4 |
Humana
HUM
|
+$51.8M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$46.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE HealthCare
GEHC
|
+$84.9M |
| 2 |
AbbVie
ABBV
|
+$69.8M |
| 3 |
Bio-Rad Laboratories Class A
BIO
|
+$57.9M |
| 4 |
Cencora
COR
|
+$57.7M |
| 5 |
argenx
ARGX
|
+$50.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VERV
76
DELISTED
Verve Therapeutics
VERV
| $3.78M | 0.15% |
285,334
-593,266
| -68% | -$9.55M |
|
77
Compass Therapeutics
CMPX
$367M
| $3.15M | 0.13% |
1,599,600
-20,600
| -1% | -$50.9K |
|
78
Altimmune
ALT
$581M
| $3.02M | 0.12% |
1,159,900
-14,200
| -1% | -$40.7K |
|
79
SCYNEXIS
SCYX
$36M
| $3.01M | 0.12% |
164,931
-52,411
| -24% | -$1.25M |
|
80
Hyperfine
HYPR
$90.9M
| $2.44M | 0.1% |
1,188,178
| – | – |
|
81
Century Therapeutics
IPSC
$370M
| $2.2M | 0.09% |
1,098,500
-12,400
| -1% | -$33K |
|
|
CMAX
82
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $1.35M | 0.05% |
21,200
| – | – |
|
|
NUVB.WS
83
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
| $8.95K | ﹤0.01% |
89,543
-1,017
| -1% | -$136 |
|
|
84
AbbVie
ABBV
$465B
| – | – |
-518,400
| Closed | -$69.8M |
|
85
Arteris
AIP
$1.34B
| – | – |
-75,500
| Closed | -$515K |
|
|
APLS
86
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-468,700
| Closed | -$42.7M |
|
87
Baxter International
BAX
$12.6B
| – | – |
-604,700
| Closed | -$27.6M |
|
88
Bausch Health
BHC
$1.69B
| – | – |
-215,100
| Closed | -$1.72M |
|
|
89
Bio-Rad Laboratories Class A
BIO
$8.86B
| – | – |
-152,600
| Closed | -$57.9M |
|
|
90
Cencora
COR
$62.2B
| – | – |
-300,000
| Closed | -$57.7M |
|
91
Denali Therapeutics
DNLI
$3.82B
| – | – |
-282,752
| Closed | -$8.34M |
|
92
Editas Medicine
EDIT
$402M
| – | – |
-3,000,000
| Closed | -$24.7M |
|
|
ETNB
93
DELISTED
89bio
ETNB
| – | – |
-526,376
| Closed | -$9.97M |
|
|
94
GE HealthCare
GEHC
$29.2B
| – | – |
-1,045,400
| Closed | -$84.9M |
|
95
Mineralys Therapeutics
MLYS
$2.38B
| – | – |
-766,700
| Closed | -$13.1M |
|
|
MRSN
96
DELISTED
Mersana Therapeutics
MRSN
| – | – |
-151,600
| Closed | -$12.5M |
|
97
Pfizer
PFE
$144B
| – | – |
-1,117,467
| Closed | -$41M |
|
98
Pliant Therapeutics
PLRX
$66.3M
| – | – |
-916,600
| Closed | -$16.6M |
|
99
Simulations Plus
SLP
$371M
| – | – |
-45,900
| Closed | -$1.99M |
|
|
SLRN
100
DELISTED
ACELYRIN
SLRN
| – | – |
-750,000
| Closed | -$15.7M |
|
Similar funds
NM
PWAM
LJAC
NI
MCM
TS
TW
PGA
Avidity Partners Management's Q3 2023 Portfolio in Review
As of Q3 2023, Avidity Partners Management held 106 positions worth $2.48B, down 13% from $2.86B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Avidity Partners Management withdrew a net $210M in Q3 2023, closing 23 positions and reducing 44 holdings. Its most notable exit was GE HealthCare, an estimated $84.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology.
Against the trend, Avidity Partners Management opened a new position in Cigna worth $59.4M.
- Avidity Partners Management's largest Q3 2023 buy was Cigna: 207,700 shares worth $59.4M.
- Avidity Partners Management added most to Boston Scientific in Q3 2023, an estimated $67.1M increase.
- Avidity Partners Management's biggest Q3 2023 reduction was argenx, cutting an estimated $50.7M.
- Avidity Partners Management fully exited GE HealthCare in Q3 2023, selling an estimated $84.9M.
- Avidity Partners Management's ten largest holdings make up 30% of its $2.48B portfolio in Q3 2023.
- Avidity Partners Management opened 13 new positions and closed 23 in Q3 2023.
- Avidity Partners Management's portfolio value fell 13% quarter-over-quarter to $2.48B.
Based on Avidity Partners Management's 13F filing for Q3 2023, filed 14 Nov 2023.